Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia.

Nucleophosmin (NPM) exon-12 mutations occur in 50% to 60% of adult acute myeloid leukemia (AML) with normal karyotype and are predictors of favorable prognosis. We evaluated bone marrow or peripheral blood samples from 450 adult patients with AML of the GIMEMA (Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto)/AML12 EORTC (European Organization for Research and Treatment of Cancer) trial to (1) search for new exon-12 NPM mutations; (2) determine whether NPM immunostaining on paraffin-embedded biopsies predicts NPM mutations; and (3) investigate altered nucleocytoplasmic NPM traffic in primary AML cells. Fourteen NPM mutations, including 8 new variants, were identified. All 200 AML cases expressing cytoplasmic NPM (NPMc(+) AML) carried NPM mutations. None of the 250 cases with nucleus-restricted NPM (NPMc(-) AML) was mutated. At the C-terminus, NPM leukemic mutants carried mutations of only tryptophan 290 or of both tryptophans 288 and 290 and a new nuclear export signal (NES) motif, which appear to underlie their nuclear export. The specific Crm1/exportin-1 inhibitor leptomycin-B relocated NPM mutants from cytoplasm to nucleus of primary NPMc(+) AML cells, demonstrating that nuclear export is NES dependent. NPM mutants bound and recruited wild-type NPM into leukemic cell cytoplasm. Because alterations at C-terminus of leukemic NPM mutants are similar, immunohistochemistry detects all exon-12 NPM mutations and is a valuable, inexpensive tool in the diagnostic-prognostic work-up of patients with AML with normal karyotype.

[1]  W. Hiddemann,et al.  Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. , 2005, Blood.

[2]  K Wheatley,et al.  The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.

[3]  P. Pandolfi,et al.  Role of nucleophosmin in embryonic development and tumorigenesis , 2005, Nature.

[4]  P. Vyas,et al.  Pathology and genetics: Tumours of haematopoietic and lymphoid tissues , 2001 .

[5]  J. Weber,et al.  ARF Impedes NPM/B23 Shuttling in an Mdm2-Sensitive Tumor Suppressor Pathway , 2004, Molecular and Cellular Biology.

[6]  B. Falini,et al.  Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations , 2006, Leukemia.

[7]  N. Bolli,et al.  Aberrant subcellular expression of nucleophosmin and NPM-MLF1 fusion protein in acute myeloid leukaemia carrying t(3;5): A comparison with NPMc+ AML , 2006, Leukemia.

[8]  W. Schaffner,et al.  Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. , 1989, Nucleic acids research.

[9]  N. Bolli,et al.  Cytoplasmic nucleophosmin in myeloid sarcoma occurring 20 years after diagnosis of acute myeloid leukaemia. , 2006, The Lancet. Oncology.

[10]  E. Jaffe.  Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues , 2003 .

[11]  X. Wang,et al.  Temporal and spatial control of nucleophosmin by the Ran–Crm1 complex in centrosome duplication , 2005, Nature Cell Biology.

[12]  T. Naoe,et al.  Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. , 2005, Blood.

[13]  B. Falini,et al.  Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. , 2002, Blood.

[14]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[15]  W. Hiddemann,et al.  Both carboxy-terminus NES motif and mutated tryptophan(s) are crucial for aberrant nuclear export of nucleophosmin leukemic mutants in NPMc+ AML. , 2006, Blood.

[16]  K. Ballen,et al.  Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 2-2005. A 39-year-old woman with headache, stiff neck, and photophobia. , 2005, The New England journal of medicine.

[17]  Stefan Fröhling,et al.  Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. , 2005, Blood.

[18]  Pamela A. Silver,et al.  Nuclear transport and cancer: from mechanism to intervention , 2004, Nature Reviews Cancer.

[19]  C. Felix,et al.  The molecular basis of leukemia. , 2004, Hematology. American Society of Hematology. Education Program.

[20]  C. Korgaonkar,et al.  Nucleophosmin (B23) Targets ARF to Nucleoli and Inhibits Its Function , 2005, Molecular and Cellular Biology.

[21]  Bob Löwenberg,et al.  Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. , 2005, Blood.

[22]  M. Okuda.  The role of nucleophosmin in centrosome duplication , 2002, Oncogene.

[23]  Gerhard Ehninger,et al.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). , 2006, Blood.

[24]  Charles J. Sherr,et al.  Physical and Functional Interactions of the Arf Tumor Suppressor Protein with Nucleophosmin/B23 , 2004, Molecular and Cellular Biology.

[25]  B. Falini,et al.  Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. , 2005, Blood.

[26]  R. Suzuki,et al.  Nucleophosmin in acute myelogenous leukemia. , 2005, The New England journal of medicine.

[27]  B. Falini,et al.  Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia , 2005, Leukemia.

[28]  Emili Montserrat,et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[29]  J. F. Wallace,et al.  CASE RECORDS OF THE MASSACHUSETTS GENERAL HOSPITAL. , 1965, The New England journal of medicine.

[30]  N. Bolli,et al.  Cell line OCI/AML3 bears exon-12 NPM gene mutation-A and cytoplasmic expression of nucleophosmin , 2005, Leukemia.

[31]  B. Falini,et al.  Denaturing high-performance liquid chromatography: a valid approach for identifying NPM1 mutations in acute myeloid leukemia. , 2006, The Journal of molecular diagnostics : JMD.

[32]  Katia Basso,et al.  Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1) , 2004, The Lancet.

[33]  C. Lehner,et al.  Major nucleolar proteins shuttle between nucleus and cytoplasm , 1989, Cell.

[34]  B Falini,et al.  Detection of normal and chimeric nucleophosmin in human cells. , 1999, Blood.

[35]  S. Pileri,et al.  Immunocytochemical diagnosis of acute promyelocytic leukemia (M3) with the monoclonal antibody PG-M3 (anti-PML). , 1997, Blood.

[36]  J. Cayuela,et al.  Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype. , 2005, Blood.

[37]  Natalia Meani,et al.  Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. , 2005, Blood.

[38]  E. Castagnola,et al.  Decline in mortality with varicella vaccination. , 2005, The New England journal of medicine.

[39]  B. Falini,et al.  Nucleophosmin Is Required for DNA Integrity and p19Arf Protein Stability , 2005, Molecular and Cellular Biology.